Valeant pays $65M upfront for U.S. rights to Eisai's Targretin

02/22/2013 | Genetic Engineering & Biotechnology News

Eisai has sold the U.S. rights to Targretin capsules and 1% gel to Valeant Pharmaceuticals for $65 million plus possible milestone fees. Valeant will handle the new drug application and other regulatory obligations in the U.S. Targretin, or bexarotene, capsules and gel are used to treat patients with skin problems associated with cutaneous T-cell lymphoma who failed to respond to at least one systemic treatment.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ